Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Metastatic Uveal Melanoma
NCT01587352Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in Uveal melanoma (UM), sponsored by National Cancer Institute. Started May 2012; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01587352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01587352.